Synairgen’s research collaboration with Pharmaxis to develop a compound to treat idiopathic pulmonary fibrosis (IPF) is a positive development and provides insight into the group’s first ‘new opportunity’. IPF is a rare disease and an indication we previously flagged as an interesting area for Synairgen. Pharmaxis/Synairgen’s approach offers a different mechanism of action from recently FDA approved IPF treatments and as such offers a differentiated approach. The first clinical trial is expected ....
05 Aug 2015
Research collaboration with Pharmaxis
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Research collaboration with Pharmaxis
Synairgen plc (SNG:LON) | 5.1 0 0.0% | Mkt Cap: 10.3m
- Published:
05 Aug 2015 -
Author:
Sheena Berry -
Pages:
4
Synairgen’s research collaboration with Pharmaxis to develop a compound to treat idiopathic pulmonary fibrosis (IPF) is a positive development and provides insight into the group’s first ‘new opportunity’. IPF is a rare disease and an indication we previously flagged as an interesting area for Synairgen. Pharmaxis/Synairgen’s approach offers a different mechanism of action from recently FDA approved IPF treatments and as such offers a differentiated approach. The first clinical trial is expected ....